|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: ZNHIT2 |
Gene summary for ZNHIT2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | ZNHIT2 | Gene ID | 741 |
| Gene name | zinc finger HIT-type containing 2 | |
| Gene Alias | C11orf5 | |
| Cytomap | 11q13.1 | |
| Gene Type | protein-coding | GO ID | GO:0003674 | UniProtAcc | Q9UHR6 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 741 | ZNHIT2 | cirrhotic3 | Human | Liver | Cirrhotic | 6.00e-04 | 8.46e-02 | 0.0215 |
| 741 | ZNHIT2 | HCC2 | Human | Liver | HCC | 2.53e-06 | 3.87e+00 | 0.5341 |
| 741 | ZNHIT2 | S014 | Human | Liver | HCC | 4.44e-20 | 6.72e-01 | 0.2254 |
| 741 | ZNHIT2 | S015 | Human | Liver | HCC | 1.90e-19 | 6.21e-01 | 0.2375 |
| 741 | ZNHIT2 | S016 | Human | Liver | HCC | 3.04e-28 | 7.77e-01 | 0.2243 |
| 741 | ZNHIT2 | S027 | Human | Liver | HCC | 6.96e-04 | 4.71e-01 | 0.2446 |
| 741 | ZNHIT2 | S028 | Human | Liver | HCC | 2.18e-17 | 5.88e-01 | 0.2503 |
| 741 | ZNHIT2 | S029 | Human | Liver | HCC | 2.53e-23 | 8.83e-01 | 0.2581 |
| 741 | ZNHIT2 | C04 | Human | Oral cavity | OSCC | 1.55e-11 | 6.09e-01 | 0.2633 |
| 741 | ZNHIT2 | C21 | Human | Oral cavity | OSCC | 6.50e-37 | 1.29e+00 | 0.2678 |
| 741 | ZNHIT2 | C30 | Human | Oral cavity | OSCC | 6.89e-09 | 5.82e-01 | 0.3055 |
| 741 | ZNHIT2 | C43 | Human | Oral cavity | OSCC | 3.38e-15 | 3.38e-01 | 0.1704 |
| 741 | ZNHIT2 | C46 | Human | Oral cavity | OSCC | 2.16e-07 | 2.90e-01 | 0.1673 |
| 741 | ZNHIT2 | C57 | Human | Oral cavity | OSCC | 2.10e-04 | 2.90e-01 | 0.1679 |
| 741 | ZNHIT2 | C08 | Human | Oral cavity | OSCC | 4.01e-13 | 3.37e-01 | 0.1919 |
| 741 | ZNHIT2 | LN22 | Human | Oral cavity | OSCC | 1.33e-03 | 5.55e-01 | 0.1733 |
| 741 | ZNHIT2 | LN46 | Human | Oral cavity | OSCC | 2.33e-03 | 2.46e-01 | 0.1666 |
| 741 | ZNHIT2 | SYSMH1 | Human | Oral cavity | OSCC | 3.01e-09 | 2.63e-01 | 0.1127 |
| 741 | ZNHIT2 | SYSMH2 | Human | Oral cavity | OSCC | 3.43e-09 | 3.44e-01 | 0.2326 |
| 741 | ZNHIT2 | SYSMH3 | Human | Oral cavity | OSCC | 2.45e-25 | 5.87e-01 | 0.2442 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| ZNHIT2 | deletion | Frame_Shift_Del | novel | c.737delG | p.Gly246AlafsTer114 | p.G246Afs*114 | Q9UHR6 | protein_coding | TCGA-EW-A2FV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD | ||
| ZNHIT2 | SNV | Missense_Mutation | c.619N>C | p.Val207Leu | p.V207L | Q9UHR6 | protein_coding | tolerated(0.16) | benign(0) | TCGA-CK-6746-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| ZNHIT2 | SNV | Missense_Mutation | novel | c.1112N>C | p.Val371Ala | p.V371A | Q9UHR6 | protein_coding | tolerated(1) | benign(0) | TCGA-AJ-A3EK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | CR |
| ZNHIT2 | SNV | Missense_Mutation | novel | c.1129G>A | p.Ala377Thr | p.A377T | Q9UHR6 | protein_coding | tolerated(0.18) | benign(0.003) | TCGA-AJ-A3OK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Chemotherapy | carboplatin | CR |
| ZNHIT2 | SNV | Missense_Mutation | novel | c.109N>G | p.Thr37Ala | p.T37A | Q9UHR6 | protein_coding | tolerated(1) | benign(0) | TCGA-AP-A1DV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| ZNHIT2 | SNV | Missense_Mutation | rs144753523 | c.1055N>T | p.Ala352Val | p.A352V | Q9UHR6 | protein_coding | tolerated(0.27) | benign(0) | TCGA-AX-A2HC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | PD |
| ZNHIT2 | SNV | Missense_Mutation | novel | c.1156N>C | p.Trp386Arg | p.W386R | Q9UHR6 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-AX-A3FT-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| ZNHIT2 | SNV | Missense_Mutation | c.720C>G | p.Phe240Leu | p.F240L | Q9UHR6 | protein_coding | tolerated(0.11) | benign(0.003) | TCGA-BG-A0MI-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| ZNHIT2 | SNV | Missense_Mutation | novel | c.249N>C | p.Glu83Asp | p.E83D | Q9UHR6 | protein_coding | tolerated(0.66) | benign(0) | TCGA-BG-A220-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| ZNHIT2 | SNV | Missense_Mutation | novel | c.125N>T | p.Ala42Val | p.A42V | Q9UHR6 | protein_coding | deleterious(0) | benign(0.046) | TCGA-DI-A1BU-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | paclitaxel | SD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |